NP Thyroid 60 38 ug/1
LEVOTHYROXINE, LIOTHYRONINE · TABLET · Northwind Health Company, LLC
NP Thyroid 60 is a tablet containing levothyroxine, liothyronine at 38 ug/1, taken oral. Manufactured by Northwind Health Company, LLC.
Key Facts
- Brand Name
- NP Thyroid 60
- Generic Name
- LEVOTHYROXINE, LIOTHYRONINE
- NDC Code (Product)
51655-132- Manufacturer
- Northwind Health Company, LLC
- Strength
- 38 ug/1
- Dosage Form
- TABLET
- Route
- ORAL
- Marketing Status
- Drug Class
- l-Thyroxine [EPC]; l-Triiodothyronine [EPC]
- Marketing Start
- 02/12/2015
Recall History
Acella Pharmaceuticals, LLC
Superpotent Drug.
Acella Pharmaceuticals, LLC
Subpotent Drug
Side Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Full Prescribing Information
Indications & Usage
INDICATIONS AND USAGE: NP Thyroid® tablets (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer.
Dosage & Administration
DOSAGE AND ADMINISTRATION: The dosage of thyroid hormones is determined by the indication and must in every case be individualized according to patient response and laboratory findings. Thyroid hormones are given orally. In acute, emergency conditions, injectable levothyroxine sodium may be given intravenously when oral administration is not feasible or desirable, as in the treatment of myxedema coma, or during total parenteral nutrition. Intramuscular administration is not advisable because of reported poor absorption. Hypothyroidism — Therapy is usually instituted using low doses, with increments which depend on the cardiovascular status of the patient. The usual starting dose is 30 mg NP Thyroid®, with increments of 15 mg every 2 to 3 weeks. A lower starting dosage, 15 mg/day, is recommended in patients with long standing myxedema, particularly if cardiovascular impairment is suspected, in which case extreme caution is recommended. The appearance of angina is an indication for a reduction in dosage. Most patients require 60 to 120 mg/day. Failure to respond to doses of 180 mg suggests lack of compliance or malabsorption. Maintenance dosages 60 to 120 mg/day usually result in nor…
Warnings
WARNINGS
Contraindications
CONTRAINDICATIONS: Thyroid hormone preparations are generally contraindicated in patients with diagnosed but as yet uncorrected adrenal cortical insufficiency, untreated thyrotoxicosis, and apparent hypersensitivity to any of their active or extraneous constituents. There is no well-documented evidence from the literature, however, of true allergic or idiosyncratic reactions to thyroid hormone.
Drug Interactions
Drug Interactions — Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired. Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started. If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required. No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy. Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparations and endocrine status of the patient. Patients receiving insulin or oral hypoglycemics should be closely watched during initiation of thyroid replacement therapy. Cholestyramine — Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid ho…
Adverse Reactions
ADVERSE REACTIONS: Adverse reactions other than those indicative of hyperthyroidism because of therapeutic overdosage, either initially or during the maintenance period, are rare (See OVERDOSAGE).
Frequently Asked Questions
What is NP Thyroid 60 used for?
NP Thyroid 60 contains LEVOTHYROXINE, LIOTHYRONINE. It is a tablet taken oral. Consult your doctor for specific uses.
Is NP Thyroid 60 a controlled substance?
NP Thyroid 60 is not classified as a controlled substance by the DEA.
What is the generic name for NP Thyroid 60?
The generic name for NP Thyroid 60 is LEVOTHYROXINE, LIOTHYRONINE. There are 9 other brand versions of LEVOTHYROXINE, LIOTHYRONINE.
What is the NDC code for NP Thyroid 60 38 ug/1?
The NDC (National Drug Code) for NP Thyroid 60 38 ug/1 is 51655-132, listed by Northwind Health Company, LLC.